%0 Journal Article
%A Saei, Ali Kian
%A Asghari, Narjes
%A Jahangiri, Babak
%A Cordani, Marco
%A Nayeri, Zahra
%A Fard, Najaf Allahyari
%A Djavaheri-Mergny, Mojgan
%A Moosavi, Mohammad Amin
%T Drug repositioning and experimental validation for targeting ZZ domain of p62 as a cancer treatment
%D 2025
%@ 0010-4825
%U https://hdl.handle.net/20.500.14352/119186
%X Cancer treatment is often confounded by development of resistance to chemotherapy. This research explores the complex relationship between p62 (also known as SQSTM1), a multifunctional protein central in cancer signaling pathways — especially the NF-κB pathway — and chemoresistance. Our data indicate that disruption of the interaction between p62 and the serine/threonine protein kinase RIP1 is a viable strategy to counteract NF-κB activation and overcome chemoresistance. Employing a comprehensive drug repositioning approach, we utilized bioinformatics tools to perform docking, virtual screening, absorption, distribution, metabolism, and excretion analyses, toxicity analysis, and molecular dynamics simulations to identify FDA-approved drugs that prevent the binding of p62 to RIP1. Notable candidates, particularly montelukast and asunaprevir, blocked the p62-RIP1 interaction, establishing a basis for potential therapeutic interventions against chemoresistant cancers. This study highlights the critical role of the ZZ domain of p62 protein in chemotherapy resistance and sheds light on the possibility of repurposing existing drugs for novel applications in cancer treatment. Our findings provide a solid groundwork for preclinical studies.
%~